Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.
about
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's DiseaseAutoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implicationsFundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease in focal cerebral ischemic ratsFundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's diseaseNatural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the AgedAlzheimer's Disease: Mechanism and Approach to Cell TherapyIntravenous immunoglobulin and Alzheimer's disease: what now?The role of tau in neurodegenerative diseases and its potential as a therapeutic target'Clinical trials in Alzheimer's disease': immunotherapy approachesPrion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic targetTau-targeted treatment strategies in Alzheimer's diseasePassive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy modelsSex and Immunogen-Specific Benefits of Immunotherapy Targeting Islet Amyloid Polypeptide in Transgenic and Wild-Type MiceTau Protein Mediates APP Intracellular Domain (AICD)-Induced Alzheimer's-Like Pathological Features in MiceTau Biology and Tau-Directed Therapies for Alzheimer's DiseaseImmunotherapeutic approaches for Alzheimer's diseaseThe Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and TherapyPropagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.Roles of tau protein in health and disease.Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model.Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potencyThe intersection of amyloid beta and tau at synapses in Alzheimer's diseaseEpitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis.Novel immunological approaches for the treatment of Alzheimer's disease.Antibody-derived in vivo imaging of tau pathology.Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificityEfficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathyTau aggregation and its interplay with amyloid-β.A generic method for design of oligomer-specific antibodies.Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration.p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice.Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies.Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer's Disease Like Tau Aggregation.Stabilization of Microtubule-Unbound Tau via Tau Phosphorylation at Ser262/356 by Par-1/MARK Contributes to Augmentation of AD-Related Phosphorylation and Aβ42-Induced Tau Toxicity.Trans-cellular propagation of Tau aggregation by fibrillar speciesDistinct Therapeutic Mechanisms of Tau Antibodies: Promoting Microglial Clearance Versus Blocking Neuronal Uptake.Sensitive quantitative assays for tau and phospho-tau in transgenic mouse modelsImmunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.
P2860
Q26739412-C16F7E5F-75E9-4DA4-B4F3-C7A5184448D9Q26740418-D96F9621-8D60-4F38-AABE-2438929452F4Q26747585-3729AF7F-4A0B-4CAA-A49C-F712DE9B7D0DQ26748713-781DD5F8-9393-421D-96F3-80180F7CC709Q26752508-12040C0B-6510-47D8-9E1E-B1B586C94C72Q26778149-8B4ACC1B-1AC4-445F-A064-2D46EA0187B7Q27000371-50442825-02FB-49A8-84DF-6C27A9525944Q27005032-94C4D3FC-54A9-4254-85AE-667B1ABE1CB4Q27008979-8BB033AB-2499-433E-B3E1-48D328599E0CQ27021159-07FF41E1-BDCE-426E-8589-8963755F3D86Q27023429-2DFC0EF2-ACCF-403A-BEB4-98AAE681EAC8Q27308146-E1A10228-142F-4E97-92E2-D8B65DF96026Q27329865-93B1682E-9DB6-4366-8D15-67DECC65D279Q27334314-4A449557-BB8A-425C-A7C4-62697152578BQ28071398-C8C25081-A290-42C1-9184-B107EDCD5A56Q28081278-D7C225E3-50AC-4E8B-92EA-5477AD51C672Q28119005-A09CAEAE-72D0-48A2-B193-F44ADB4D2E74Q31024674-C1EF0A33-23F0-4EE3-A3E2-E3F1C496E753Q33559303-E2891C63-0DF0-4634-A4E7-42DC9BA5E65DQ33603862-B18CA04A-CE89-4414-A5F4-0B581DA48C46Q33640390-9DC16B5D-5E6B-4ECD-9B0E-74F4A489B717Q34054680-2E162E86-042F-4980-9EB6-87DEC27013C8Q34205027-4A8612AF-ECF3-4AA7-9D03-74D29A38E600Q34562675-FC5B9EB0-99E3-46C1-9986-F7A992410AA4Q34664345-27CB3D3B-F659-4E2D-85EE-DEA040127608Q34701388-FBFFC258-93A2-4FB2-B2E7-E032D536E59CQ34973787-B9BC7C88-4432-4E85-A295-A68881C50327Q35008256-359C49D7-35F4-4553-910E-8FDBCB65AD55Q35117526-E5ABDE1C-D115-41B4-95D0-BC459E6DBA47Q35204878-7D66A40E-6B56-4BF2-88D5-BC9CE789F36AQ35542169-197FEA92-6CD9-42D5-9FD9-3F3DA60A6C32Q35624263-1F771292-4F37-41F4-97E8-38583DA64708Q35745135-657C4AB7-A4EB-4CE7-BD8A-F25352B57F1AQ35826638-9E220F3C-37EA-4CDE-87D0-FAF47040F41EQ35972860-FC127F5B-9ABC-4BA9-90D6-04DEFD4E6BC3Q36003836-2A9F4B32-29A7-4F13-BD85-E99EC227A716Q36065130-63763842-1BDC-484E-B4BD-3484CCBCB325Q36328476-8C308335-A159-44A5-B1EC-5CD1B4187DDFQ36484413-BB05DB27-5BA0-4D2B-8C00-2872D93D0A49Q36558485-22CC32D9-6AAB-4D07-8165-99F3578EA8E0
P2860
Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Passive immunization targeting ...... tau aggregates from the brain.
@ast
Passive immunization targeting ...... tau aggregates from the brain.
@en
type
label
Passive immunization targeting ...... tau aggregates from the brain.
@ast
Passive immunization targeting ...... tau aggregates from the brain.
@en
prefLabel
Passive immunization targeting ...... tau aggregates from the brain.
@ast
Passive immunization targeting ...... tau aggregates from the brain.
@en
P2860
P1476
Passive immunization targeting ...... tau aggregates from the brain.
@en
P2093
Allal Boutajangout
Johanna Ingadottir
P2860
P304
P356
10.1111/J.1471-4159.2011.07337.X
P407
P577
2011-07-01T00:00:00Z